What Is Familial Adenomatous Polyposis (FAP)?

Familial adenomatous polyposis (FAP) is an inherited condition in which hundreds to thousands of small growths called polyps develop along the lining of the large intestine, typically beginning in adolescence. Left untreated, these polyps progress to colorectal cancer in virtually every affected person, usually by their forties. FAP is caused by a mutation in a single gene passed from parent to child, making it the most common gastrointestinal polyposis syndrome. But the condition reaches well beyond the colon, and the decisions it forces on patients and their families are anything but simple.

The Genetic Root

FAP traces back to mutations in the APC gene, located on chromosome 5. The condition follows an autosomal dominant inheritance pattern, meaning you only need one faulty copy of the gene to develop the disease.¹ If a parent carries the mutation, each child has a 50 percent chance of inheriting it. Roughly a quarter to a third of new cases, however, arise without any family history at all. These are called de novo mutations, where the gene change occurs spontaneously in the affected person for the first time.² One case report described a 43-year-old man with no family history of cancer who presented with hundreds of colon polyps and rectal cancer, found to carry a previously undetected APC mutation.³ That reality means an absence of affected relatives does not rule out FAP.

The APC protein normally acts as a brake on cell growth. It works within a molecular complex that tags a signaling molecule called beta-catenin for destruction. When the APC gene is mutated and the protein no longer functions, beta-catenin accumulates and switches on genes that drive cells to multiply, a feature found in nearly all colorectal cancers.⁴ ⁵ Each polyp essentially represents a tiny patch of cells where the remaining good copy of APC has also been knocked out, allowing that growth-promoting pathway to run unchecked.

What Happens in the Colon

The hallmark of classic FAP is the sheer number of polyps. In a large pediatric series, colon polyps appeared by a mean age of about 13, though some children had them as young as eight months old. At the time of diagnosis, roughly 60 percent of patients already had more than 50 polyps, and polyps most often blanketed the entire colon.⁶ Most of the polyps in that series showed low-grade dysplasia, meaning the cells looked abnormal under a microscope but had not yet become cancerous. Still, one 18-year-old in the series already had invasive cancer at the first colonoscopy.⁶

Without intervention, the progression from polyps to cancer is considered inevitable. The average age of cancer development in untreated classic FAP is the late thirties to early forties. That timeline is why screening and preventive surgery take place so early in life compared with screening recommendations for the general population.

Attenuated FAP and Related Syndromes

Not everyone with an APC mutation develops the carpet of polyps seen in classic FAP. A milder form called attenuated adenomatous polyposis (AAP) produces fewer polyps, typically between 10 and 99, and cancer tends to develop later in life.⁷ The distinction matters for management because patients with attenuated disease may not need the same aggressive surgical approach or the same surveillance schedule as those with classic FAP.

Historically, several overlapping labels have described APC-driven conditions. Gardner syndrome refers to FAP combined with bony growths (osteomas), skin cysts, and other soft-tissue tumors. Turcot syndrome describes the combination of colorectal polyposis with brain tumors, especially medulloblastomas.⁸ These are now understood as different expressions of the same underlying APC mutation rather than truly separate diseases. The specific location of the mutation along the gene influences which symptoms predominate.

Where the Mutation Sits Changes the Disease

One of the more useful discoveries in FAP genetics is that the position of the APC mutation predicts, at least in broad strokes, how severe the disease will be and which organs beyond the colon are likely to be affected. Mutations in the middle region of the gene tend to produce the classic colon-heavy picture. Mutations beyond codon 1403 are associated with more varied and often more aggressive extracolonic features.⁹

A Japanese study found that patients with mutations in codons 1398 through 1580 had particularly high rates of severe desmoid tumors, extensive stomach polyps, and advanced duodenal disease.¹⁰ This kind of genotype-phenotype mapping helps guide clinicians in deciding how aggressively to screen each organ system and what type of surgery to recommend. It also explains why two family members with the same mutation can still have somewhat different clinical pictures, though their general risk profile will be similar.

Beyond the Colon

FAP is best known for what it does to the colon, but the APC gene is active throughout the body, and its effects extend to multiple organs. These extracolonic manifestations can be just as medically significant as the colon polyps themselves.

Duodenal Polyps

Polyps in the duodenum, the first section of the small intestine, are nearly universal in FAP patients over time. A long-running study found that by age 70, about 90 percent of patients had developed duodenal adenomas.¹¹ The good news is that only a small fraction, roughly 1 to 5 percent, go on to develop actual duodenal cancer.¹² But that risk grows with the number and size of polyps, so regular upper endoscopy is standard care for anyone with FAP. In the duodenal study, the cumulative cancer rate was about 4.5 percent by age 57, with higher risk in patients whose polyps had already reached a severe stage at their first examination.¹¹

Desmoid Tumors

Desmoid tumors are fibrous growths that develop in connective tissue, most commonly in the abdomen. They are not cancerous in the conventional sense, as they do not spread to distant organs, but they can grow aggressively into surrounding structures and cause serious complications. Roughly 10 to 15 percent of FAP patients develop desmoid disease, and it most often occurs after abdominal surgery.¹³ This creates a frustrating catch-22: the surgery that prevents colon cancer can itself trigger desmoid growth in susceptible individuals.

A retrospective study of over 200 FAP patients who underwent colorectal surgery found that about 10 percent developed intra-abdominal desmoid tumors afterward. Open surgery carried higher risk than laparoscopic approaches, and removing the rectum along with the colon roughly tripled the hazard compared with rectal-sparing operations. A family history of desmoid tumors also increased risk.¹⁴ For high-risk patients, this information directly influences which type of surgery is recommended and when.

Other Extracolonic Features

FAP can also produce thyroid and pancreatic cancers, liver tumors (hepatoblastomas, mostly in young children), brain tumors, adrenal adenomas, osteomas of the jaw and skull, and dental abnormalities like extra teeth or unerupted teeth.¹⁵ A painless bony lump on the jaw or a thyroid nodule in a teenager can sometimes be the first clue to an undiagnosed FAP case, particularly in families without a known history.

Diagnosis and Genetic Testing

FAP is diagnosed through a combination of colonoscopy, clinical features, and genetic testing. When a colonoscopy reveals more than 100 adenomatous polyps, the clinical picture is essentially diagnostic. Genetic testing for APC mutations then confirms it and, just as importantly, allows cascade testing of other family members. Relatives who test negative for the family mutation are spared from the intensive surveillance schedule, while those who test positive can begin screening early enough to prevent cancer.¹⁶

For children with an affected parent, genetic testing is generally offered during early adolescence, around age 10 to 12, since polyps can begin developing in the early teens. If the family mutation is known, a blood test settles the question. If it is not, colonoscopic surveillance starts around the same age and continues annually or every two years.

MUTYH-Associated Polyposis

A condition that looks a lot like FAP under the colonoscope but arises from a completely different genetic mechanism is MUTYH-associated polyposis, or MAP. It accounts for about 7 percent of patients who present with an adenomatous polyposis pattern and is caused by mutations in the MUTYH gene rather than APC.¹⁷ The key difference is inheritance: MAP is autosomal recessive, meaning a person needs two faulty copies of the gene, one from each parent, to develop the disease. This changes the math for families. Carriers of a single MUTYH mutation are generally healthy, but two carrier parents have a one-in-four chance of having an affected child. When APC testing comes back negative in someone with multiple colon polyps, MUTYH testing is the natural next step.

Surgical Options

Because cancer is otherwise inevitable, preventive removal of the colon is the central treatment for FAP. The decision is not whether to operate but when and how much to remove. The main surgical options are:

Total colectomy with ileorectal anastomosis (IRA): The colon is removed but the rectum is preserved and connected to the small intestine. This avoids a permanent ostomy bag and tends to result in better day-to-day bowel function, but the remaining rectum still carries polyp and cancer risk and requires lifelong surveillance.
Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA): Both the colon and rectum are removed, and a pouch fashioned from the small intestine is connected to the anus. This eliminates rectal cancer risk but involves a more complex surgery and typically results in more frequent bowel movements.
Total proctocolectomy with permanent ileostomy: The entire colon and rectum are removed and an ostomy bag is placed. This is reserved for situations where the other options are not feasible, such as very low rectal cancers or severe desmoid disease.

A decision analysis comparing the two main options found that ileorectal anastomosis provided better quality-adjusted life expectancy in about 87 percent of modeled scenarios, though total life expectancy was similar between the two approaches.¹⁸ The rectal-sparing operation, however, requires that patients commit to regular surveillance of the remaining rectal tissue, since polyps will continue to develop there.¹⁹ A study comparing quality of life between the two procedures found that generic and disease-specific quality of life was similar, though both groups scored lower than the general population on standardized health surveys.²⁰

The choice between procedures depends on the density and distribution of rectal polyps, the patient’s desmoid risk profile, their age, and their preferences regarding bowel function and surveillance burden. In patients at high risk for desmoid tumors, a rectal-sparing approach with a laparoscopic technique may be preferred precisely because the more extensive operation carries greater desmoid risk.²¹

Can Medication Slow Things Down?

Researchers have long sought drugs that could reduce the polyp burden in FAP, either to delay surgery or to manage polyps that recur after it. Anti-inflammatory drugs have shown the most promise. A meta-analysis found that NSAIDs reduced polyp number by about 17 percent and polyp size by about 16 percent compared to placebo, though the certainty of the evidence was rated low.²² Sulindac and celecoxib are the two drugs studied most, and both have been shown to shrink polyps in the retained rectum after colectomy.²³

There is an important caveat. When sulindac was tested as a primary prevention agent in young people who had the APC mutation but had not yet developed polyps, it did not slow their development. Polyps appeared at similar rates and sizes in both the sulindac and placebo groups.²⁴ So these medications appear to work on existing polyps rather than preventing new ones from forming, and they do not replace the need for surgery. Research into lower-dose drug combinations and newer agents like curcumin and fish-oil-derived eicosapentaenoic acid continues, though results so far come from small trials.²³

The Gut Microbiome Connection

An emerging area of research examines how the bacterial community in the gut may influence the pace at which polyps progress to cancer in FAP. Studies using mouse models that mimic the condition have found that specific changes in the intestinal microbial community can influence the adenoma-to-carcinoma sequence, the multi-step process by which a benign polyp transforms into a malignancy. The proposed mechanisms include injury to the gut’s protective lining, low-grade chronic inflammation, and amplification of the same growth-promoting pathway that APC mutations unleash.²⁵ This research is still in early stages. No microbiome-based therapy has been proven to alter outcomes in FAP patients, but the work raises the possibility that the bacterial environment in the colon might eventually become a modifiable factor alongside genetics and surgery.

Telling Your Children and Planning a Family

Few aspects of FAP are as emotionally complex as deciding when and how to tell your children they may have inherited the condition, and whether to pursue genetic testing. Testing is typically offered around age 10 to 12, balancing the medical benefit of early surveillance against the psychological weight of a positive result. A systematic review of studies on the psychological impact of genetic testing in children found that serious adverse effects were uncommon in the short term, with most children’s anxiety and depression scores remaining in the normal range after testing.²⁶ However, the picture was not universally reassuring. Some studies found small, non-significant increases in depressive symptoms, and children whose parent was already affected by FAP seemed to fare less well. One study reported that about one in ten children who tested positive regretted being tested, and another found that more than a third of tested children met criteria for a psychiatric diagnosis afterward.²⁶

Genetic counselors who work with FAP families emphasize that the process of testing matters as much as the result itself. Actively supporting adolescents’ developing sense of autonomy, giving them age-appropriate information, and acknowledging the emotional weight of the result all contribute to better outcomes.²⁷

For adults with FAP who are thinking about having children, reproductive options have expanded. Prenatal testing can identify whether a fetus carries the family’s APC mutation, and preimplantation genetic diagnosis allows couples using in vitro fertilization to select embryos that do not carry it.²⁸ Surveys show that many FAP patients are willing to consider prenatal testing to prevent passing the condition to their children, though values and decisions vary widely among individuals and families.²⁹ These are deeply personal choices, and there is no single right answer. What matters most is that families know these options exist before conception, when the greatest number of paths remain open.

1
PubMed Central. Familial adenomatous polyposis
2
PubMed Central. The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management
3
PubMed Central. De novo familial adenomatous polyposis with germline double heterozygosity of APC/BRCA2: a case report and literature review
4
PubMed Central. Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting
5
PubMed. Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells
6
Journal of Pediatric Surgery. Management and clinical course of pediatric familial adenomatous polyposis
7
PubMed Central. Attenuated adenomatous polyposis of the large bowel: Present and future
8
PubMed. A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome
9
PubMed Central. Correlation between the development of extracolonic manifestations in FAP patients and mutations beyond codon 1403 in the APC gene
10
PubMed Central. Genotype–phenotype correlation for extracolonic aggressive phenotypes in patients with familial adenomatous polyposis
11
PubMed Central. Duodenal adenomatosis in familial adenomatous polyposis
12
PubMed Central. Duodenal adenoma surveillance in patients with familial adenomatous polyposis
13
PubMed Central. Updates and controversies for desmoids in familial adenomatous polyposis
14
BJS Open. Risk factors and protective measures for desmoid tumours in familial adenomatous polyposis: retrospective cohort study
15
PubMed Central. Extra-intestinal manifestations of familial adenomatous polyposis
16
PubMed Central. APC gene testing for familial adenomatosis polyposis
17
PubMed Central. Updated European guidelines for clinical management of familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), gastric adenocarcinoma, proximal polyposis of the stomach (GAPPS) and other rare adenomatous polyposis syndromes
18
Diseases of the Colon & Rectum. A Decision Analysis for Rectal-Sparing Familial Adenomatous Polyposis: Total Colectomy With Ileorectal Anastomosis Versus Proctocolectomy With IPAA
19
PubMed. Current management of familial adenomatous polyposis
20
PubMed. Quality of life after total colectomy with ileorectal anastomosis or proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis
21
PubMed Central. Surgical management of the colorectum in FAP: tailored approaches for optimal outcomes
22
Gastrointestinal Advances. Efficacy of Nonsteroidal Anti-inflammatory Drugs on Colorectal Polyp Burden in Patients With Familial Adenomatous Polyposis: A Systematic Review and Meta-analysis
23
PubMed Central. Chemoprevention in familial adenomatous polyposis
24
PubMed Central. Primary chemoprevention of familial adenomatous polyposis with sulindac
25
PubMed Central. Familial adenomatous polyposis and changes in the gut microbiota: New insights into colorectal cancer carcinogenesis
26
Genetics in Medicine. The psychological impact of genetic information on children: a systematic review
27
PubMed. The challenge of developmentally appropriate care: predictive genetic testing in young people for familial adenomatous polyposis
28
PubMed Central. Attitudes toward genetic testing in childhood and reproductive decision-making for familial adenomatous polyposis
29
PubMed. Attitudes toward prenatal genetic testing in patients with familial adenomatous polyposis